UroGen Pharma (URGN) Return on Capital Employed (2018 - 2026)
UroGen Pharma's (URGN) quarterly Return on Capital Employed came in at 61.33% in Q1 2026, down 1328.0% YoY from 4.99% in Q1 2025, and up 28.12% on a QoQ basis from 85.33% in Q4 2025.
UroGen Pharma (URGN) Return on Capital Employed (2018 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 9 years of Return on Capital Employed data on file, last reported at 61.33% in Q1 2026.
- Quarterly Return on Capital Employed fell 1328.0% year-over-year to 61.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 61.33% (down 1328.0% YoY) and the FY2025 annual result came in at 63.49%, down 1147.0% from the prior year.
- Return on Capital Employed rose to 61.33% in Q1 2026, from 85.33% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 32.32% in Q3 2024 to a low of 97.94% in Q2 2023.
- A 5-year average of 61.98% and a median of 61.33% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 5944 bps — and 2025, when it plunged 5395 bps.
- Tracing URGN's Return on Capital Employed over 5 years: stood at 73.1% in 2022, then surged by 42 bps to 42.35% in 2023, then climbed by 8 bps to 39.04% in 2024, then slumped by 119 bps to 85.33% in 2025, then rose by 28 bps to 61.33% in 2026.
- The last three Return on Capital Employed figures came in at 61.33% (Q1 2026), 85.33% (Q4 2025), and 86.27% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -34.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.86% |
| Mar 31, 2026 | -61.33% |
| Dec 31, 2025 | -85.33% |
| Sep 30, 2025 | -86.27% |
| Jun 30, 2025 | -68.41% |
| Mar 31, 2025 | -48.05% |
| Dec 31, 2024 | -39.04% |
| Sep 30, 2024 | -32.32% |
| Jun 30, 2024 | -38.50% |
| Mar 31, 2024 | -42.45% |
| Dec 31, 2023 | -42.35% |
| Sep 30, 2023 | -59.99% |
| Jun 30, 2023 | -97.94% |
| Mar 31, 2023 | -79.89% |
| Dec 31, 2022 | -73.10% |
| Sep 30, 2022 | -66.50% |
| Jun 30, 2022 | -60.94% |
| Mar 31, 2022 | -71.28% |
| Dec 31, 2021 | -88.07% |
| Sep 30, 2021 | -80.10% |